PLx Pharma Winddown Corp.: 10-K filed 2015-03-23

Name: PLx Pharma Winddown Corp.: 10-K filed 2015-03-23
Creator: PLx Pharma Winddown Corp.

What PLx Pharma Winddown Corp. reported in its annual report filed 2015-03-23 (fiscal FY 2014): 13 published measures, 24 facts as tagged in accession 0001047469-15-002607.

This filing

Form: 10-K (annual report)
Filed: 2015-03-23
Fiscal period: fiscal FY 2014
Accession: 0001047469-15-002607 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PLx Pharma Winddown Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-12-31	27,209,838	USD
At 2013-12-31	4,030,065	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-12-31	1,260,598	USD
At 2013-12-31	823,834	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-12-31	27,040,325	USD
At 2013-12-31	3,861,145	USD
At 2012-12-31	1,457,115	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-13,580,984	USD	365
2013-01-01 to 2013-12-31	-4,013,620	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-12-31	-22,318,749	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	0	USD	365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	1,418,312	USD	365
2013-01-01 to 2013-12-31	1,077,777	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-13,580,984	USD	365
2013-01-01 to 2013-12-31	-4,013,620	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-12-31	27,160,453	USD
At 2013-12-31	3,907,239	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	13,580,984	USD	365
2013-01-01 to 2013-12-31	4,013,620	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-12-31	8,538,329	shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2014-12-31	49,385	USD
At 2013-12-31	122,826	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	4,682,704	USD	365
2013-01-01 to 2013-12-31	2,284,080	USD	365

Inspect the source

Entity: PLx Pharma Winddown Corp. / CIK 0001497504
Captured: 2026-09-22 19:50 UTC
SEC response SHA-256: d5fa1894253c4a7ca3d44f3b07f2263d07de14ac7e8983994cead4448c203364

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001497504.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))